
World's first silicon-based quantum computer is small enough to plug into a regular power socket
A startup has launched the first quantum device in the world that blends the potential of quantum computing with the convenience and integration of traditional high-performance computing (HPC).
Equal1 representatives unveiled Bell-1 on March 16 — a new six- qubit machine that can fit seamlessly into existing HPC environments like data centers, company representatives said in a statement .
The machine tips the scale at slightly more than 440 pounds (200 kilograms) but it's rack-mountable — meaning it can be mounted onto a physical rack in a data center — and it's roughly the same size as existing graphics processing unit (GPU) servers.
Unlike other quantum computers, the Bell-1 doesn't require specialized infrastructure to deploy, and it doesn't need additional equipment to be cooled to near-absolute zero.
Related: China achieves quantum supremacy claim with new chip 1 quadrillion times faster than the most powerful supercomputers
That's because it boasts its own self-contained, closed-cycle cryo cooling unit, which enables the system to operate at a remarkable 0.3 kelvin, or minus 459.13 degrees Fahrenheit (minus 272.85 degrees Celsius).
The machine makes use of the latest semiconductor fabrication techniques as well as purified silicon , which allows for a high level of control and long coherence times (a qubit's ability to exist in multiple states simultaneously, which is crucial for quantum algorithms and computations).
Get the world's most fascinating discoveries delivered straight to your inbox.
Rack-mountable quantum computing
The Bell-1's qubits are silicon-based, meaning they're smaller than conventional qubits, and the chip at the heart of the machine incorporates quantum processor units (QPUs) with Arm CPUs — traditional processors known for their small size and efficiency — and neural processing units (NPUs) — specialized processors for accelerating machine learning and artificial intelligence (AI).
Incorporating all these elements onto a single chip eliminates the complex orchestration that would otherwise be necessary between classical and quantum computing elements. As long as you've got the space in a rack, all it requires is a standard electrical outlet: plug it in and it's ready to work, Equal1 representatives said.
(Image credit: Fergal Phillips)
The company's chip, called the UnityQ 6-Qubit Quantum Processing System, utilizes spin qubits, in contrast to many quantum computing platforms that rely on either trapped-ion or superconducting qubits. Silicon-based spin qubits are compact, leading to potentially higher qubit density, and could leverage existing semiconductor fabrication techniques, meaning more scalability.
The chip fitted into the Bell-1 also incorporates error correction, control and readout, while taking advantage of existing semiconductor infrastructure for reliability and scalability.
Although this first generation of the chip includes six qubits, the company wants to make more powerful versions with a higher qubit count. The Bell-1 is also future-proof in that early adopters can upgrade existing systems as new models are rolled out, rather than replacing them with new machines, company representatives added.
The Bell-1 builds on advances first published by the company in December 2024, which established new peak performance marks for silicon qubit arrays as well as quantum controller chips.
These included the world's highest recorded single-qubit and two-qubit gate fidelity (meaning fewer errors) and gate speed (meaning faster operations). The platform also utilizes a specialized, AI-powered error correction system developed in partnership with Arm.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Is Celsius Holdings Stock a Buy Now?
Celsius stock is up over 50% this year. The company acquired competitor Alani Nu in April. Celsius' revenue growth is set to recover, but mostly because of its purchase of Alani Nu. 10 stocks we like better than Celsius › After massive declines in the second half of last year, Celsius Holdings (NASDAQ: CELH) stock may finally be ready for a comeback. The company's rapid growth came to a sudden halt (at least temporarily) as sluggish demand led one of its major distributors (likely PepsiCo) to dramatically scale back its orders. The beverage stock is down over 60% since its peak in early 2024. Still, it is up over 50% since the beginning of the year. The question for investors is whether that recovery signifies the beginnings of a Celsius comeback, or whether investors need to stay on the sidelines. Celsius has carved out a compelling, lucrative niche within the energy drink industry. Instead of pursuing customers like its larger competitors, Red Bull and Monster Beverage, Celsius targeted fitness enthusiasts. It also participated in clinical studies to validate the health benefits of its beverages. Celsius' beverages first became available in 2009. However, it was its distribution agreement with PepsiCo in August 2022 that helped sales take off. Since that agreement in the third quarter of 2022, quarterly revenues have increased by 75% even after the recent slowdown in sales. Additionally, that figure does not account for Celsius' takeover of Alani Nu, which occurred in the second quarter of this year. Before that purchase, Celsius also claimed approximately 11% of the market share, putting it in third place in the energy drink market. Still, investors should remember that it leads the health and fitness-oriented niche in the market, which will likely make it a major force in this industry. Amid the stock's partial recovery, Celsius sells at a price-to-earnings (P/E) ratio of 127. Nonetheless, since it is recovering from last year's slump, the forward P/E ratio of 50 may better reflect the company's valuation, a level coming off historical lows. It is also well below the forward P/E ratio of 125 from the stock's peak in early 2024. That forward multiple arguably brings the stock price more in line with its current growth. Unfortunately, investors may still balk at Celsius' valuation as they brace for slower growth. In the first quarter of 2025, revenue of $329 million dropped by 7% yearly. That's a dramatic improvement over the 31% decline in Q3. Still, it is well below the 102% revenue gain in 2023. The falling revenue also led to a comprehensive income in Q1 of $37 million, well below the $63 million in the year-ago quarter. Revenue growth should improve in the near term due in part to the Alani Nu takeover. In 2025, analysts forecast 60% revenue growth. But once Celsius benefits from that one-time bump, they expect the revenue increase rate to slow to 21% in 2026. Knowing that, the most significant hope for bulls may lie in the company's potential internationally, where 96% of the world's population resides. Even though international sales made up 7% of revenue in Q1 2025, that part of the market grew revenue by 41% annually. Moreover, that revenue share was only 4% one year ago. Assuming it can continue to increase the proportion of international sales significantly, Celsius stock could deliver higher returns if revenue growth abroad remains strong. Over the long term, Celsius stock likely remains a buy. Admittedly, the 50 forward P/E ratio could point to some overvaluation in the near term. Furthermore, the immediate recovery in revenue will probably happen because of the buyout of Alani Nu, rather than an organic increase in Celsius brand products. Nonetheless, the 21% forecasted revenue increase in 2026 is an indication that demand will rise over time. Additionally, even though international growth will take some time, sales outside of North America are likely to become the company's primary revenue driver over time. Such potential indicates that Celsius' growth story is far from over, meaning its stock could still be positioned for huge gains. Before you buy stock in Celsius, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Celsius wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Will Healy has positions in Celsius. The Motley Fool has positions in and recommends Celsius and Monster Beverage. The Motley Fool has a disclosure policy. Is Celsius Holdings Stock a Buy Now? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data